Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
December 19, 2022 08:00 ET
|
Assembly Biosciences, Inc.
In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction...
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
November 14, 2022 08:00 ET
|
Assembly Biosciences, Inc.
Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB),...
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
November 08, 2022 16:05 ET
|
Assembly Biosciences, Inc.
Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Assembly...
Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor
July 20, 2022 16:10 ET
|
Arbutus Biopharma Corporation
Triple combination clinical trial evaluating AB-729, an RNAi therapeutic, vebicorvir, Assembly Biosciences’ core inhibitor, and nucleos(t)ide analog continues with data expected in 2H 2022 ...
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus
February 26, 2021 07:30 ET
|
Arbutus Biopharma Corporation; Assembly Biosciences, Inc.
Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy SOUTH SAN FRANCISCO, Calif., and WARMINSTER,...
Assembly Biosciences Announces Key Additions to Microbiome Team
September 28, 2016 07:00 ET
|
Assembly Biosciences
INDIANAPOLIS, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing novel oral therapeutics for disorders associated with the human...
Assembly Biosciences Announces Participation in HBV Scientific Meetings in China and South Korea
September 21, 2016 07:30 ET
|
Assembly Biosciences
INDIANAPOLIS, Sept. 21, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus...
Assembly Biosciences to Present at the Jefferies 2016 Global Healthcare Conference
June 01, 2016 07:30 ET
|
Assembly Biosciences, Inc.
NEW YORK, June 01, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV)...
Assembly Biosciences to Present Data at The International Liver Congress(TM) 2016 that Supports Advancing Its CpAM Candidates into HBV Clinical Trials
April 13, 2016 07:00 ET
|
Assembly Biosciences, Inc.
—In Preclinical Studies, Novel Class of Core Protein Allosteric Modifiers (CpAMs) Showed Potent Antiviral Activity, No Cytotoxicity and Good Pharmacokinetic Properties— —Planning to Start Phase 1...
Assembly Biosciences to Present Data on New Series of HBV Core Protein Allosteric Modifiers at The International Liver Congress™ 2016
March 30, 2016 07:30 ET
|
Assembly Biosciences, Inc.
BARCELONA, Spain and NEW YORK, March 30, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic therapeutics for...